Analysts Set Quince Therapeutics, Inc. (NASDAQ:QNCX) Target Price at $9.50

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCX) have received a consensus rating of “Buy” from the six brokerages that are covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $9.50.

Several research analysts have weighed in on QNCX shares. Brookline Capital Management started coverage on shares of Quince Therapeutics in a research report on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price on the stock. D. Boral Capital restated a “buy” rating and set a $12.00 target price on shares of Quince Therapeutics in a research report on Wednesday, February 5th.

Quince Therapeutics Trading Up 0.7 %

Shares of QNCX opened at $1.38 on Tuesday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The firm’s 50-day moving average is $1.50 and its two-hundred day moving average is $1.43. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The firm has a market capitalization of $60.72 million, a P/E ratio of -1.11 and a beta of 0.71.

Institutional Trading of Quince Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC lifted its holdings in shares of Quince Therapeutics by 10.9% in the fourth quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock valued at $703,000 after purchasing an additional 36,807 shares in the last quarter. Shay Capital LLC lifted its stake in shares of Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock valued at $518,000 after buying an additional 104,616 shares during the period. Scharf Investments LLC purchased a new position in shares of Quince Therapeutics during the fourth quarter valued at approximately $170,000. Northern Trust Corp lifted its stake in shares of Quince Therapeutics by 48.5% during the fourth quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after buying an additional 16,501 shares during the period. Finally, Two Sigma Investments LP purchased a new position in shares of Quince Therapeutics during the fourth quarter valued at approximately $57,000. Hedge funds and other institutional investors own 30.75% of the company’s stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.